Table 3.
Key randomized phase III trial with targeted agents as salvage treatment for gastric cancer.
| Trial name | Selected biomarker | Treatment | Number of patients | Primary endpoint | Hazard ratio (95% confidence interval) | p value | Median OS (months) |
|---|---|---|---|---|---|---|---|
| TyTAN[Satoh et al. 2014b] | HER2 amplification by FISH | PaclitaxelPaclitaxel+lapatinib | 129132 | OS | 0.84 (0.64–1.1) | 0.1044 | 8.911 |
| REGARD[Fuchs et al. 2014] | All comers | BSCBSC+ramucirumab | 117238 | OS | 0.776 (0.603–0.998) | 0.047 | 3.85.2 |
| RAINBOW[Wilke et al. 2014] | All comers | PaclitaxelPaclitaxel+ramucirumab | 335330 | OS | 0.807 (0.678–0.962) | 0.017 | 7.49.6 |
| NCT01512745[Li et al. 2014] | All comers | PlaceboApatinib | 92181 | OS | 0.71 (0.54–0.94) | 0.016 | 4.66.4 |
| GRANITE[Ohtsu et al. 2013] | All comers | BSCBSC+everolimus | 217439 | OS | 0.90 (0.75–1.08) | 0.124 | 4.35.4 |
BSC, best supportive care; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; OS, overall survival.